Eupraxia Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EPRXF research report →
About the company
Eupraxia Pharmaceuticals Inc. operates as a clinical-stage biotechnology firm, focusing its efforts on the discovery, advancement, and commercialization of innovative technologies within the biotech landscape. The company's leading therapeutic compound, EP-104IAR, is currently progressing through Phase II clinical trials.
- CEO
- James A. Helliwell FRCPC,
- IPO
- 2021
- Employees
- 21
- HQ
- Victoria, BC, CA
Price Chart
- Market Cap
- $108.29M
- P/E
- -6.39
- P/S
- 0.00
- P/B
- 2.76
- EV/EBITDA
- -4.14
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -50.81%
- ROIC
- -32.53%
- Revenue
- $0 · 0.00%
- Net Income
- $-38,089,240 · -63.76%
- EPS
- $-1.58 · -30.58%
- Op Income
- $-37,889,260
- FCF YoY
- -46.79%
- 52W High
- $6.78
- 52W Low
- $2.93
- 50D MA
- $4.30
- 200D MA
- $4.80
- Beta
- 1.40
- Avg Volume
- 2.42K
Get TickerSpark's AI analysis on EPRXF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our EPRXF coverage
Recent articles, reports, and earnings notes.
No research on EPRXF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EPRXF report →Similar companies
Peers in the same neighborhood.